News
Turning Crisis into Strategy: Contracts, projects and disputes at a global chokepoint
The Delaware Court of Chancery (the “Court”) rang in the new year with a decision in which it broadly interpreted a contract provision commonly included in license agreements to address royalty monetization arrangements, determining that such provision also applied to a secured financing. While reaction to this decision has been mixed among practitioners, the Court's ruling raises several practice points for attorneys handling any licensing transaction, secured financing, or other commercial contract.
First, the specifics of the case. The Court decided a number of claims in a summary judgment motion in a dispute over rights under an exclusive license between Zevra Therapeutics, Inc. (the “licensor”) and Commave Therapeutics SA (the “licensee”).[1] Of primary importance to the present discussion was the applicability of certain restrictions on the licensor’s right to sell or transfer to a third party its right to receive payments under the license agreement without first offering the licensee a right to match any third-party offer for such rights. Citing Black’s Law Dictionary, the Court concluded that the security interest in the license granted by the licensor as part of a loan transaction qualified as either an “assignment” or “transfer” subject to the license restrictions. Relying on the maxim “expressio unus est exclusio alterius” (the express mention of one matter implies the exclusion of others), the Court further noted that the parties had expressly carved out an existing collateral loan from the provision, implying that all other loans would be included within the restriction. The ruling also provided that the anti-assignment provisions of the Uniform Commercial Code and an “Excluded Assets” provision (a concept explained in more detail below) in the financing documentation did not apply.
It remains to be seen whether the Court’s decision will be upheld if there is an appeal, and it is unclear if the parties had intended for the restrictions on assigning or transferring payment rights to capture ordinary course secured loans, rather than the more bespoke royalty monetization transactions usually targeted by these provisions. With the court adopting a broad interpretation of the provision, we highlight a handful of practice points of which to be mindful in drafting such provisions going forward.
[1] Commave Therapeutics SA v. Zevra Therapeutics, Inc., No. 2024-0920-LWW, 2025 WL 3778938 (Del. Ch. Dec. 31, 2025).
Authored by Anishiya Abrol, Cullen Taylor, Edward Purdon, and Nathan Cooper
This article is part of our thought leadership series, “Life Sciences Transactional Insights,” which aims to provide key practical takeaways for our transactional colleagues by anticipating the needs of their regulatory, intellectual property, and business stakeholders. Our dedicated team of life sciences and health care licensing and commercial transactions lawyers understand the challenges and opportunities that strategic alliances and other partnering relationships present. We draw on the depth of our life sciences practice and work seamlessly with our regulatory experts to provide unparalleled transactional support. Ensure you are subscribed to "Our Thinking" to receive our insights.